Bacterial Vaginosis. Inflammatory diseases of female pelvic organs
Conditions
Interventions
Intervention 1: Intervention group will receive vitamin C vaginal tablet 250 mg which produced by Faculty of Medicine Pharmaceutical group in Tabriz university of medical science with oral metronida
Treatment - Drugs
Placebo
Intervention group will receive vitamin C vaginal tablet 250 mg which produced by Faculty of Medicine Pharmaceutical group in Tabriz university of medical science with oral metronidazole ( prescribe
Control group will receive placebo vaginal tablet along with oral metronidazole ( prescribed with the dose of 500 mg twice a day) during 7 days.
Sponsors
Tabriz University of Medical Sciences. Women’s Reproductive Health Research Center
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: non-pregnant and non breastfeeding married women age between 18 -45 Years Old,diagnosis of bacterial vaginosis with contemporary presence of at least three out of four Amsel criteria and gain score 4 to 6 with clue cells or score 7 to 10 without clue cells in Nugent scoring system, have willing to participate to study , possibility to attending center in schedule time for post treatment follow up , husband’s monogamous , Filling the Informed Consent Form; Exclusion criteria: chronic disease , consumption of vaginal medication or douching during the recent weeks , Immune deficiency syndrome, consumption of antibiotic during the recent weeks , consumption of rifampin –phenytoin- phenobarbital and any anticoagulant agents , other vaginal infections ,presence of unknown vaginal bleeding .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical and laboratory criteria based on Amsel and Nugent scoring system . Timepoint: Before intervention, 10 ± 1 and 30 ± 3 days after treatment. Method of measurement: Measured by clinical measurements of diseases and laboratory tests.;Malodon discharge. Timepoint: Before intervention, 10 ± 1 and 30 ± 3 days after treatment. Method of measurement: Measured by asking from patient.;Itching. Timepoint: Before intervention, 10 ± 1 and 30 ± 3 days after treatment. Method of measurement: Measured by asking from patient.;Dyspareunia. Timepoint: Before intervention, 10 ± 1 and 30 ± 3 days after treatment. Method of measurement: Measured by asking from patient.;Having fishy smell during sexual intercourse. Timepoint: Before intervention, 10 ± 1 and 30 ± 3 days after treatment. Method of measurement: Measured by asking from patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| The vaginal PH change. Timepoint: Before intervention, 10 ± 1 and 30 ± 3 days after treatment. Method of measurement: PH paper scale.;Change in Clue Cells. Timepoint: Before intervention, 10 ± 1 and 30 ± 3 days after treatment. Method of measurement: Measured by laboratory tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSevil Hakimi
Tabriz University of Medical Sciences
Outcome results
None listed